Histone Deacetylase Inhibitors Research

The paper identifies HDAC4 as a synthetic lethal target in MELK-overexpressing cancers through a yeast screen and mammalian validation.

This study identifies p300 and HDAC1 as enzymes regulating Api5 acetylation and deacetylation, showing their impact on Api5 stability and cell cycle progression.

The paper investigates synthetic lethality in vorinostat-resistant HCT116 colon cancer cells, finding that resistance is linked to rewiring of oncogenic pathways rather than embryonal gene regulation.

This study shows that reducing HDAC2 in hiPSC-derived neurons enhances mitochondrial function and reduces neurotoxic amyloid beta, suggesting HDAC2's role in neuronal maturation and disease.

The paper shows that inhibiting HDAC2 with ASOs increases cortical acetylcholine and dopamine signaling via a CREB-Gs positive feedback loop, enhancing cognition.

This study identifies HDAC1 as a mediator of nicotine-induced cisplatin resistance in NSCLC cells, showing nicotine promotes growth by targeting HDAC1 and modulating E2F and Cyclin E expression.

The paper investigates how paralog switching affects Sin3 complex interaction networks in humans, revealing shared and distinct interactions between SIN3A and SIN3B.

This study identifies MiDAC as a regulator of neurodevelopmental gene expression by modulating histone acetylation and neurite outgrowth.

This study investigates the effects of HDAC inhibitors in RSTS models, showing molecular rescue and microbiota changes, and highlights the role of gut microbiota in chromatinopathy.

This study shows HDAC6 promotes PMA-induced megakaryocyte differentiation in K562 cells by increasing ROS via NOX4 and repressing the erythroid marker GYPA.